Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 2,377 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Questionnaire 1 Clear all
Active, not recruiting Phase 1Phase 2 Interventional

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

NCT02726997
View directory record Official record
Conditions
Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7, Stage IIIA Fallopian Tube Cancer AJCC v7, Stage IIIA Ovarian Cancer AJCC v6 and v7, Stage IIIA Primary Peritoneal Cancer AJCC v7, Stage IIIB Fallopian Tube Cancer AJCC v7, Stage IIIB Ovarian Cancer AJCC v6 and v7, Stage IIIB Primary Peritoneal Cancer AJCC v7, Stage IIIC Fallopian Tube Cancer AJCC v7, Stage IIIC Ovarian Cancer AJCC v6 and v7, Stage IIIC Primary Peritoneal Cancer AJCC v7, Stage IV Fallopian Tube Cancer AJCC v6 and v7, Stage IV Ovarian Cancer AJCC v6 and v7, Stage IV Primary Peritoneal Cancer AJCC v7
Interventions
Carboplatin, Durvalumab, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 4, 2026, 10:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Remote Dietary Counseling to Promote Healthy Diet and Blood Pressure

NCT03700710
View directory record Official record
Conditions
Blood Pressure, High Blood Pressure, Dietary Modification, Overweight and Obesity
Interventions
Self-Guided Approach, Dietitian-led Approach
Behavioral
Lead sponsor
Geisinger Clinic
Other
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Nov 4, 2026, 10:53 AM EST
Active, not recruiting Not applicable Interventional

A Study of a Pelvic Floor Muscle Exercise Program Before and After Radical Prostatectomy

NCT06671782
View directory record Official record
Conditions
Prostate Cancer
Interventions
Kegel exercises, Pelvic Floor Muscle Exercise Program with biofeedback, Questionnaires, Interviews
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Nov 4, 2026, 10:53 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention

NCT01282580
View directory record Official record
Conditions
Breast Cancer
Interventions
Lovaza-Omega 3 fatty acid capsules, Dietary fish (canned salmon, albacore)
Dietary Supplement · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 30, 2019 · Synced Nov 4, 2026, 10:53 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of Noninvasive Neuromodulation on Mental Wellness, Behavior, and Electrophysiology

NCT06169631
View directory record Official record
Conditions
Anxiety Disorders
Interventions
Gen0b
Device
Lead sponsor
Sanmai Technologies PBC dba Sanmai
Industry
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Nov 4, 2026, 10:53 AM EST
Completed Not applicable Interventional

Comparing (SIS.NET) to Standard Care in Patients Who Have Completed the Acute Phase of Treatment for Early Breast Cancer

NCT01308775
View directory record Official record
Conditions
Breast Cancer
Interventions
SIS.NET, Routine Follow-up
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Nov 4, 2026, 10:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies

NCT01377857
View directory record Official record
Conditions
HIV
Interventions
Monetary Incentive, Questionnaire Timing, HIV Test Offering
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
13 Years to 64 Years
Enrollment
8,572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Nov 4, 2026, 10:53 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression

NCT02417064
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Nov 4, 2026, 10:53 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes

NCT02863172
View directory record Official record
Conditions
Hereditary Colorectal Cancer Syndrome
Interventions
Questionnaires, Blood Draw/Saliva Sample
Behavioral · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 4, 2026, 10:53 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

The Ohio State University (OSU) SCREEN Community Program

NCT06666192
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Colorectal Carcinoma
Interventions
Cancer Screening, Discussion, Educational Activity, Educational Intervention, Focus Group, Health Care Delivery, Health Promotion, Health Promotion and Education, Health Risk Assessment, Implementation, Informational Intervention, Internet-Based Intervention, Interview, Outreach, Patient Navigation, Survey Administration
Other · Behavioral · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
2,067 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Nov 4, 2026, 10:53 AM EST
Completed Phase 2 Interventional Results available

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

NCT00711828
View directory record Official record
Conditions
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Bortezomib, Rituximab, Cyclophosphamide, Dexamethasone, Questionnaire Administration, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Nov 4, 2026, 10:53 AM EST
Completed Not applicable Interventional Results available

Insulin Detemir Compared to Insulin Glargine: Appetite and Calories Consumed in Type 1 Diabetes

NCT00659165
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin Detemir, Insulin Glargine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Nov 4, 2026, 10:53 AM EST
Completed No phase listed Observational

Prognostic Value of Rb-82 PET Myocardial Perfusion Imaging

NCT01474577
View directory record Official record
Conditions
Cardiac Health
Interventions
questionnaire
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Nov 4, 2026, 10:53 AM EST
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation

NCT03602898
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions
Anti-Thymocyte Globulin, Busulfan, Cyclophosphamide, Cyclosporine, Fludarabine Phosphate, Methotrexate, Peripheral Blood Stem Cell Transplantation, Quality-of-Life Assessment, Questionnaire Administration, Tacrolimus, Total-Body Irradiation
Biological · Drug · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Nov 4, 2026, 10:53 AM EST
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Nov 4, 2026, 10:53 AM EST
Terminated Phase 2Phase 3 Interventional Results available

The Use of Light Therapy for Managing Sleep Disturbances in Patients With Advanced Cancer

NCT01193530
View directory record Official record
Conditions
Advanced Cancers
Interventions
Bright Light Therapy, Dim Red Light Therapy, Questionnaires, Study Diaries, Red Light Litebook, Bright Light Litebook
Other · Behavioral · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Nov 4, 2026, 10:53 AM EST
Suspended Not applicable Interventional

Virtual Reality in Reducing Pain and Anxiety in Cancer Participants Undergoing Painful Procedures

NCT03568292
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Best Practice, Laboratory Biomarker Analysis, Oculus Rift Headset, Questionnaire Administration
Other · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 4, 2026, 10:53 AM EST
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Calcium-Rich Food Versus Calcium Carbonate for Bone Health

NCT07763509
View directory record Official record
Conditions
Osteopenia, Osteoporosis, Bone Health in Perimenopausal Women, Menopause Related Conditions, Fracture Healing
Interventions
500 mg calcium from milk-derived minerals, Calcium Carbonate 500 MG
Other · Dietary Supplement
Lead sponsor
Cornell University
Other
Eligibility
40 Years to 90 Years · Female only
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Nov 4, 2026, 10:53 AM EST
Completed Not applicable Interventional

Art Therapy for Caregivers of Young Patients Undergoing Bone Marrow Transplant for Cancer

NCT00922285
View directory record Official record
Conditions
Health Status Unknown, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial support for caregiver, questionnaire administration, quality-of-life assessment, stress management therapy
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Nov 4, 2026, 10:53 AM EST
Completed No phase listed Observational

Quality of Life Assessed With the PAH SYMPACT Questionnaire

NCT03905421
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 25, 2025 · Synced Nov 4, 2026, 10:53 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients

NCT04633616
View directory record Official record
Conditions
Psoriasis, Atopic Dermatitis, Acne
Interventions
Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Nov 4, 2026, 10:53 AM EST
Active, not recruiting Phase 2 Interventional

A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

NCT04195399
View directory record Official record
Conditions
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Nirogacestat Hydrobromide, Quality-of-Life Assessment, Questionnaire Administration, X-Ray Imaging
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 18 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
89
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 4, 2026, 10:53 AM EST
Not listed Not applicable Interventional

Monitoring and Self-management of Sleep Fatigue and Dyspnea

NCT04434716
View directory record Official record
Conditions
Heart Failure Patients
Interventions
Feasibility of wearing a Readiband to monitor Sleep and Fatigue
Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
30 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Nov 4, 2026, 10:53 AM EST
Terminated Phase 2 Interventional Results available

Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load

NCT04336943
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Interventions
Durvalumab, Olaparib, Quality-of-Life Assessment, Questionnaire Administration
Biological · Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Nov 4, 2026, 10:53 AM EST